Replies to post #208819 on Biotech Values

[DewDiligence]

IPH.PA questions viability of Lirilumab program (licensed to BMY):

http://www.innate-pharma.com/en/news-events/press-releases/innate-pharma-provides-update-lirilumab

While lirilumab was shown to be well-tolerated, the assessment of efficacy from the ongoing exploration of doublet combinations, notably the nivolumab combination in an extended population of SCCHN patients, did not provide clear evidence of benefit to patients or an obvious development path.

This PR came out after the close of trading today in Paris, so we can’t ascertain the effect on the share price.

Lirilumab has had some previous failures (#msg-128489648). Fortunately for BMY, the up-front payment in the Lirilumab licensing deal was only $35M.

IPH.PA is holding a CC today at 12:30pm ET.